首页> 外国专利> METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19

METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19

机译:基于益生菌菌株肠球菌L3的Covid-19创建活疫苗的方法和活疫苗肠球菌L3-PENTF-Covid-19

摘要

FIELD: medicine; virology; microbiology; molecular genetics; biotechnology. ;SUBSTANCE: invention relates to medicine, virology, microbiology, molecular genetics and biotechnology. Presented is a live vaccine Enterococcus faecium L3-pentF-covid-19, containing a clone of enterococci COVID 19+ with a DNA region SEQ ID No: 1 introduced into its genome, providing expression of a protein having the amino acid sequence SEQID No: 2, stimulating humoral and cellular immunity in against the SARS-CoV-2 virus. Also presented is a method of obtaining the specified vaccine based on the probiotic strain Enterococcus faecium L3, modified as a result of electroporation of the culture of enterococci Enterococcus faecium L3 of the recombinant plasmid DNA pentF-covid-19, SEQ ID No: 1, characterized by the fact that the the pspf region of the plasmid pentF-pspf is replaced by a fragment of the gene of the SARS-CoV-2 spike protein, while the pentF-covid-19 DNA encodes the amino acid sequence SEQ ID No: 2, which functions as the spike protein of the SARS-CoV-2 virus, capable of stimulating humoral and cellular immunity against SARS-CoV-2 virus. ;EFFECT: oral administration of the Enterococcus faecium pentF-covid-19 vaccine stimulates the development of a specific systemic and local immune response, which is manifested by the production of specific immunoglobulins of classes G and A, as well as increased production of interferon gamma in vaccinated animals.;2 cl, 7 dwg, 1 tbl, 5 ex
机译:领域:医学;病毒学;微生物学;分子遗传学;生物技术。 ;物质:发明涉及药物,病毒学,微生物学,分子遗传学和生物技术。呈现的是一种活疫苗肠球菌粪便,含有DNA区域SEQ ID NO:1的肠球菌Covid 19+的克隆,其中引入其基因组,提供具有氨基酸序列的蛋白质的表达SEQID NO: 2,刺激对抗SARS-COV-2病毒的体液和细胞免疫。还提出了一种基于益生菌菌株肠球菌粪便的指定疫苗的方法,其被修饰,由于重组质粒DNA PETF-Covid-19,SEQ ID NO:1的肠球菌肠球菌培养物的培养物的电穿孔,其特征在于,质粒PELF-PSPF的PSPF区域被SARS-COV-2穗蛋白的基因的片段取代,而PELF-Covid-19 DNA编码氨基酸序列SEQ ID NO: 2,其作为SARS-COV-2病毒的尖峰蛋白,能够刺激对抗SARS-COV-2病毒的体液和细胞免疫力。 ;效果:口服肠球菌粪便施用粪便粪便 - Covid-19疫苗刺激了特异性全身和局部免疫应答的发展,这表现为课程G和A的特异性免疫球蛋白的产生,以及增加干扰素γ的产生在接种疫苗的动物中。; 2 cl,7 dwg,1 tbl,5例

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号